Discussion about this post

User's avatar
James Emanuel's avatar

Novo Nordisk's new milestone. Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA for people with type 2 diabetes. It offers people an alternative to daily basal insulin injections, reducing these injections from seven to only one per week. Aside from convenience, this development has large benefits to the unit economics, both for Novo Nordisk and its customers. Novo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026.

James Emanuel's avatar

NOVO NORDISK (NVO) share price drops 25%

The market's sharp reaction to Novo Nordisk's guidance cut may be disproportionate given that the company's first-half 2025 performance remained robust: sales increased by 18% and operating profit rose 29% at constant exchange rates, demonstrating healthy underlying demand and execution despite the revised second-half outlook. Although it should be noted that non-recurring accounting adjustments and cost control contributed to some of the operating profit outperformance in the first half.

Novo Nordisk now expects sales growth of 8–14% and operating profit growth of 10–16%, both at constant exchange rates. This is a significant reduction from the previous forecasts of 13–21% and 16–24%, respectively - and the market took that news badly.

However, the weaker guidance, which looks excessively conservative, is largely attributable to anticipated lower sales growth in the second half, rather than an immediate deterioration of fundamentals. The guidance cut was driven in part by competition from copycat compounded versions of Wegovy in the US, which are unauthorized formulations made by compounding pharmacies. Novo Nordisk is proactively pursuing legal action to block these unapproved versions, which, if successful, would restore a more favorable market landscape and support future sales growth.

31 more comments...

Ready for more?